SCHEMBL5378602

SCHEMBL5378602

CS(=O)(=O)OC[C@@H]1C(c2c(F)cc(NC(=O)OCc3ccccc3)cc2F)[C@@H]1COS(C)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.45
POLB P06746 1/20 0.44
PTPN1 P18031 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
ENPP2 Q13822 3/20 0.41
KDM1A O60341 2/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RCOR1 Q9UKL0 1/20 0.40
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14197105 0.88 MGLL (0.48) MGLLPOLBPTPN1NPC1RAB9A
SCHEMBL4874563 0.88 MGLL (0.48) MGLLPOLBPTPN1NPC1RAB9A
SCHEMBL5378627 0.83 MGLL (0.51) MGLLPOLBPTPN1NPC1RAB9A
SCHEMBL14370631 0.83 MGLL (0.51) MGLLPOLBPTPN1NPC1RAB9A
SCHEMBL5369903 0.77 MGLL (0.49) MGLLPOLBNPC1RAB9AENPP2
SCHEMBL14370633 0.77 MGLL (0.49) MGLLPOLBNPC1RAB9AENPP2
SCHEMBL14055465 0.75 POLB (0.59) MGLLPOLBNPC1RAB9APTGDR2
SCHEMBL5373964 0.74 NPC1 (0.49) MGLLPOLBPTPN1NPC1RAB9A
SCHEMBL5592076 0.74 MGLL (0.56) MGLLPOLBPTPN1NPC1RAB9A
SCHEMBL5592144 0.73 KDM1A (0.51) MGLLPOLBPTPN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279494-B2 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues PFIZER INC. (US) 2007-10-09 US disclosed
EP-1615916-A1 ANTIMICROBIAL 3.1.0 BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES Pharmacia & Upjohn Company LLC (US) 2006-01-18 EP disclosed
US-20050192325-A1 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues RENSLO ADAM (US) 2005-09-01 US disclosed
WO-2004089943-A1 ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192325-A1 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues OXA1L, CYP51A1, CYP2C19 MGLL 1507/4885POLB 979/4885PTPN1 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.